Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E21.72 EPS (ttm)1.79 Insider Own16.40% Shs Outstand2.57B Perf Week-1.19%
Market Cap99.89B Forward P/E13.00 EPS next Y3.00 Insider Trans0.00% Shs Float2.30B Perf Month-8.68%
Income4.69B PEG3.39 EPS next Q0.84 Inst Own10.30% Short Float0.12% Perf Quarter-5.51%
Sales38.48B P/S2.60 EPS this Y4.10% Inst Trans4.18% Short Ratio1.15 Perf Half Y0.86%
Book/sh23.73 P/B1.64 EPS next Y-1.80% ROA- Target Price51.67 Perf Year-17.68%
Cash/sh2.73 P/C14.27 EPS next 5Y6.40% ROE- 52W Range36.11 - 49.79 Perf YTD-4.88%
Dividend1.66 P/FCF- EPS past 5Y-4.40% ROI6.50% 52W High-21.80% Beta1.01
Dividend %4.26% Quick Ratio1.00 Sales past 5Y0.50% Gross Margin68.90% 52W Low7.81% ATR0.53
Employees115631 Current Ratio1.50 Sales Q/Q-54.00% Oper. Margin- RSI (14)33.48 Volatility1.24% 1.07%
OptionableYes Debt/Eq0.32 EPS Q/Q-56.00% Profit Margin- Rel Volume0.58 Prev Close38.79
ShortableYes LT Debt/Eq0.27 EarningsJul 29 BMO Payout- Avg Volume2.32M Price38.93
Recom2.30 SMA20-2.68% SMA50-4.42% SMA200-3.00% Volume1,337,559 Change0.36%
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Aug-29-16 04:46PM  [$$] Regeneron Can Generate Big Returns for Investors at
04:21PM  Mylan To Launch Its Own EpiPen Generic Rival At Half Price
02:39PM  How Will Regeneron (REGN) Stock React to Cholesterol Drug Trial Success?
01:28PM  Gilead Was Smart to Let Medivation Slip Through its Fingers
10:47AM  John Paulson Bought These 5 Stocks -- but the Charts Say Sell
10:05AM  Whats the Story behind the Pfizer-Medivation Deal?
09:33AM  Regeneron/Sanofi Present Positive Phase III Praluent Data
02:00AM  Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016 PR Newswire
01:10AM  Zika Virus Vaccine Overturns Pharma Industry Playbook (GSK, SNY, ION) at Investopedia
Aug-28-16 02:34PM  Sanofi's Risk Increases on Acquisition Miss
Aug-27-16 09:12AM  These Next-Generation Cholesterol Drugs Could Raise U.S. Healthcare Costs by $119 Billion a Year at Motley Fool
Aug-26-16 04:28PM  Week In Review: 'Strengthened' Yellen, Mylan EpiPen Furor, Best Buy Hot, Dollar Stores Pinched
11:06AM  What Do Analysts Think about BioMarins Return Potential?
10:46AM  ETFs with exposure to Sanofi : August 26, 2016
08:20AM  Sanofi Just Cant Catch a Break, Knocking at Major Support Again at 24/7 Wall St.
Aug-25-16 04:40PM  Tone-Deaf Mylan Provides Election-Year Fodder at Motley Fool
11:22AM  How Mylan's EpiPen Fight Could Sting Investors at The Wall Street Journal
09:27AM  Sanofi :SNY-US: Earnings Analysis: Q1, 2016 By the Numbers : August 25, 2016
Aug-24-16 04:06PM  Mylan Falls After Being Called Out on Price Increases -- Should You Worry?
11:04AM  Medivation: The Latest Analyst Recommendations
11:01AM  10 Stocks Billionaire John Paulson Is Buying for 2016
Aug-23-16 09:48AM  Regeneron Stock Up on BARDA Deal for MERS Antibodies
09:44AM  4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss at
09:30AM  3 Best Dividend Stocks Owned by Warren Buffett at Kiplinger
09:04AM  This Changed Sanofis Profitability in 2Q16
04:50AM  Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised)
Aug-22-16 11:05PM  The $150 million winner and the losers in Pfizer's $14 billion takeout of Medivation at
05:32PM  In possible $14 billion ending, Medivation goes back to early days at
04:29PM  Pfizer-Medivation Deal Reignites Biotech Buyout Speculation
04:13PM  Pfizer-Medivation Close to Signing $14B Acquisition Deal? (revised)
02:43PM  Betting on BioMarin at Bloomberg
02:05PM  Medivation Scores Premium in Sale to Pfizer
01:14PM  Biotechs Rise on Bet Medivation Losers Will Look to Next Deal
01:14PM  Why Did Novos Valuation Multiple Fall Recently?
01:14PM  How Did Novos Diabetes and Obesity Care Segment Perform in 1H16?
12:12PM  Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back at TheStreet
11:59AM  Pfizer Expands Cancer Platform With High-Priced Medivation Acquisition at Morningstar
11:57AM  Biotech stocks rally as investors bet on the next big tie-up at CNBC
11:54AM  FDAs Sanofi SA (ADR) (SNY) Delay Highlights Some Red Flags With IGlarLixi at Insider Monkey
11:16AM  Medivation's Shares Soar on Confirmation of a Pfizer Buyout at Motley Fool
11:16AM  BioMarin (BMRN) Stock Surges on Takeover Speculation
11:04AM  How Merial Contributes to Sanofis Growth
10:39AM  Understanding Medivations Premium Valuation
10:26AM  More Squawk from Jim Cramer: Pfizer Buys Medivation (MDVN) for $14 Billion
10:20AM  Pfizer Won the Bidding War for Medivation But Is It Really a Win? at
10:06AM  Pfizer buys Medivation $14 billion cash
09:53AM  Pfizer Will Buy Cancer Drugmaker Medivation For $14 Billion
09:29AM  Sanofi Diabetes Combination Drug FDA Action Date Extended
09:09AM  Pfizer boosts cancer drug pipeline with $14 bln Medivation deal
09:04AM  Inside the Performance of Sanofis Human Vaccines Segment in 2Q16
08:31AM  Pfizer to Buy Medivation for $14B, Boost Cancer Franchise
08:28AM  Sanofi says talked with Medivation, but will be "disciplined" acquirer
07:25AM  Pfizer Tops Sanofi in $14 Billion Medivation Deal
07:07AM  Pfizer Confirms $14 Billion Takeover of Cancer Drugmaker Medivation
06:58AM  Sanofi's Hostility Backfires at Bloomberg
06:54AM  Pfizer Trumps Sanofi With Medivation Deal for $14 Billion
06:54AM  Pfizer Beats Out Sanofi to Take Medivation in $14 Billion Deal at Bloomberg
03:54AM  Pfizer-Medivation Close to Signing $14B Acquisition Deal?
Aug-21-16 07:15PM  Pfizer nears deal to acquire Medivation for close to $14 bln -sources
Aug-19-16 11:04AM  What Happened to Sanofis Consumer Healthcare and Generics Franchise in 2Q16?
09:04AM  How Much Did Sanofis Established Prescription Products Affect Growth in 2Q16?
Aug-18-16 02:27PM  Mylans EpiPen price increases are Valeant-like in size, Shkreli-like in approach at MarketWatch
12:50PM  How Much Medivation Can Really Fetch in a Buyout at 24/7 Wall St.
11:10AM  What Are the Opportunities for Horizon in 2016?
11:04AM  Behind Sanofis Diabetes and Cardiovascular Performance in 2Q16
09:06AM  Genzyme Continued to Boost Growth for Sanofi in 2Q16
Aug-17-16 05:05PM  Understanding Sanofis Growth Drivers in 2Q16
05:05PM  Inside Sanofis Valuation Changes
04:32PM  Merck Among Drug Giants Looking To Buy Medivation, Says Report
Aug-16-16 11:00AM  Amgen, Sanofi Cholesterol Drugs Not Cost-Effective, Study Says at Bloomberg
09:05AM  Valeant: Are the Salix and Dermatology Portfolios Recovering?
Aug-15-16 12:58PM  What CVS and Express Scripts' Drug Exclusion Lists Means for Your Portfolio
Aug-13-16 07:46AM  Dengue Immunization Public Program in Parana State of Brazil Set To Achieve WHO 2020 Ambition PR Newswire
Aug-11-16 12:36PM  Will Pluristem Therapeutics Inc. (PSTI) Succeed in CLI Where Sanofi SA (ADR) (SNY) Failed? at Insider Monkey
Aug-10-16 03:45PM  Immune Design (IMDZ) Posts Wider-than-Expected Q2 Loss
09:07AM  An Update on Analyst Recommendations for Novo
Aug-09-16 03:40PM  How Did Novo Nordisk Perform across Geographies in 1H16?
03:40PM  A Look at Novos 2Q16 Revenue and Earnings
10:30AM  MDGN: Several Upcoming Milestones Including NFC-1 ADHD Phase 2/3 Data
Aug-08-16 05:46PM  How Did Regeneron Perform in 2Q16?
04:27PM  Walt Disney, CyberArk, LGI Homes, Lumentum Earnings: Investing Action Plan
Aug-05-16 04:51PM  Novo Nordisk Plunges On Guidance Cut As Diabetes Sales Struggle
11:07AM  An Update on Shires Upcoming Milestones
Aug-04-16 04:44PM  Regeneron Stock Dips As Earnings Beat And Revenue Lags
11:33AM  Regeneron (REGN) Tops Q2 Earnings, Keeps '16 Eylea View
11:03AM  Regeneron: EPS Beat and 21% Revenue Growth Not Enough to Impress; Shares Down 4.4% at
10:52AM  [$$] EU Waves Through Sanofi-Boehringer Merger at The Wall Street Journal
05:34AM  EU clears Sanofi acquisition of Boehringer division AFP
Aug-03-16 02:44PM  New Analyst Reports for Google, Chevron, Altria & Others
09:05AM  GlaxoSmithKlines Consumer Healthcare Grows in 2Q16
Aug-02-16 09:08AM  Is BioMarin Set to Become Profitable in 2017?
Aug-01-16 05:19PM  Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y
04:47PM  What Do Analysts Recommend for Novo?
03:16PM  Pokèmon Go Reflects the Increasingly Lucrative Business of Mobile Gaming
01:16PM  Pokèmon Go Is Just the Tip of the Mobile-Gaming Iceberg
11:07AM  How Much Did Kalydeco Add to Vertexs Top Line?
07:30AM  [$$] Business Watch at The Wall Street Journal
05:26AM  With latest swing, Peninsula biotech tries to double up Lou Gehrig's disease at
Jul-29-16 04:38PM  AbbVie, Merck Beat Earnings Estimates, But Sanofi Lags
03:46PM  CDC: May see more 'homegrown' Zika cases in coming weeks
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJun 14Buy363.8664,73123,552,85923,418,396Jun 16 05:47 PM
Sanofi10% OwnerFeb 17Buy393.7180,00031,496,72823,353,665Feb 18 05:45 PM
Sanofi10% OwnerFeb 16Buy391.2381,15731,751,18223,273,665Feb 18 05:45 PM
Sanofi10% OwnerJan 12Buy465.0483,93839,034,66023,192,508Jan 14 05:46 PM
Sanofi10% OwnerNov 03Buy10.00900,0009,000,0003,218,899Nov 05 02:37 PM
Sanofi10% OwnerOct 06Buy472.3311,0405,214,51923,108,570Oct 08 05:50 PM
Sanofi10% OwnerOct 06Buy459.7180,53837,024,19723,097,530Oct 08 05:45 PM